Active, not recruitingNo phase
SUCCESS (SelUtion, Safety, effiCaCy, hEalth economicS and promS) PTA Study
Key facts
- Who runs it
- M.A. Med Alliance S.A.
- Where
- Argentina, Germany, Greece, Netherlands, Singapore, Slovakia, Switzerland, and United Kingdom27 sites in 8 countriesChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 723 people enrolled
- Started
- 8 Feb 2021
- Expected to end
- 31 Dec 2028
- Type of study
- Interventional
- Treatments tested
- SELUTION SLR™ (Sustained Limus Release) drug eluting balloon (DEB)
- Record updated
- 6 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Subject age is ≥ 18 years
- Subject is able and willing to provide informed consent
- Subject is suitable for treatment with a MedAlliance SELUTION SLR DEB according to the current Instruction for use
Who cannot take part
- In the opinion of the treating investigator the subject has a life expectancy of less than 12 months
- In the opinion of the treating investigator the subject is unlikely to comply with the study follow-up regime
This trial has no sites in United States.
It has sites in 8 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
Open label, real-world, prospective, multi-center, single arm, post-market surveillance study of the SELUTION SLR™ (Sustained Limus Release) drug eluting balloon (DEB).
The group in the trial
- SELUTION SLR™ DEBTreatment being tested
Med Alliance SELUTION SLR™ 018 DEB Sirolimus Eluting Balloon Catheter.
Treatment: SELUTION SLR™ (Sustained Limus Release) drug eluting balloon (DEB)
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Record updated
- 6 November 2026